Swiss Re has released a report highlighting the role of genomics in the insurance industry, particularly in claims and litigation. The report, “Genomics: Litigation Risks and Rewards,” suggests that genomic evidence is being used in personalized medicine and healthcare, as well as in personal injury and mass tort litigation. Insurers, especially those in the healthcare and physician medical malpractice sectors, need to be aware of the increasing affordability of genetic testing and its implications on medical practices. Casualty insurers should also consider genomics as it can provide new ways to defend cases involving individual injury and mass tort.
Source and Details